Treatment of COVID-19 With Conestat Alfa, a Regulator of the Complement, Contact Activation and Kallikrein-Kinin System

Treatment of COVID-19 With Conestat Alfa, a Regulator of the Complement, Contact Activation and Kallikrein-Kinin System

A dysregulated immune response with hyperinflammation is observed in patients with severe coronavirus disease 2019 (COVID-19). The aim of the present study was to assess the safety and potential benefits of human recombinant C1 esterase inhibitor (conestat alfa), a complement, contact activation and...

Full description

Bibliographic Details
Main Authors: Pascal Urwyler, Stephan Moser, Panteleimon Charitos, Ingmar A. F. M. Heijnen, Melanie Rudin, Gregor Sommer, Bruno M. Giannetti, Stefano Bassetti, Parham Sendi, Marten Trendelenburg, Michael Osthoff
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-08-01
Series:Frontiers in Immunology
Subjects:
COVID-19
C1 esterase inhibitor
SARS-CoV-2
inflammation
complement system
kallikrein-kinin system
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2020.02072/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2020.02072/full

Similar Items